LadRx Corporation (CYTR) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Los Angeles, CA, アメリカ. 現CEOは Steven Kriegsman.
CYTR を有する IPO日 1986-11-10, 3 名の正社員, に上場 Other OTC.
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
